Morgan Stanley
BMY.RT

Morgan Stanley’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Morgan Stanley’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,858,642
Closed -$1.97M – 7723
2020
Q4 		$1.97M Sell
2,858,642
-865,177
-23% -$1.84M ﹤0.01% 4171
2020
Q3 		$8.38M Sell
3,723,819
-189,627
-5% -$542K ﹤0.01% 2190
2020
Q2 		$14M Sell
3,913,446
-1,773,285
-31% -$6.4M ﹤0.01% 1681
2020
Q1 		$21.6M Buy
5,686,731
+1,398,490
+33% +$4.61M 0.01% 1225
2019
Q4 		$12.9M Buy
+4,288,241
New +$11.2M ﹤0.01% 2116

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Morgan Stanley's BMY.RT Position: Q1 2021 in Review

Morgan Stanley sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 2,858,642 shares — an estimated $1.97M sold.

Morgan Stanley first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $21.6M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Morgan Stanley reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Morgan Stanley sold 2,858,642 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1.97M.
  • Morgan Stanley first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Morgan Stanley's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $21.6M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Morgan Stanley's 13F filing for Q1 2021, filed 17 May 2021.